SCHEMBL2135456

SCHEMBL2135456

CCCCCCCCC(=O)C=CC=CC=CC=CC=CC(=O)O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.63
KDM4E B2RXH2 1/20 0.63
PPARG P37231 7/20 0.54
PPARA Q07869 7/20 0.54
ALOX12 P18054 2/20 0.54
POLB P06746 1/20 0.51
POLA1 P09884 1/20 0.51
ACHE P22303 1/20 0.51
BACE1 P56817 1/20 0.51
OXER1 Q8TDS5 1/20 0.50
PPARD Q03181 5/20 0.48
HDAC11 Q96DB2 4/20 0.48
TSHR P16473 3/20 0.48
GPR84 Q9NQS5 3/20 0.48
ALDH1A1 P00352 2/20 0.48
TLR2 O60603 2/20 0.48
TDP1 Q9NUW8 2/20 0.48
FABP4 P15090 2/20 0.48
PTPN1 P18031 2/20 0.48
SLC22A6 Q4U2R8 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16040409 1.00 TRPA1 (0.63) TRPA1KDM4EPPARGPPARAALOX12
SCHEMBL28149740 1.00 TRPA1 (0.63) TRPA1KDM4EPPARGPPARAALOX12
SCHEMBL2538214 1.00 TRPA1 (0.63) TRPA1KDM4EPPARGPPARAALOX12
SCHEMBL18730282 1.00 TRPA1 (0.63) TRPA1KDM4EPPARGPPARAALOX12
SCHEMBL887711 1.00 TRPA1 (0.63) TRPA1KDM4EPPARGPPARAALOX12
SCHEMBL18730280 1.00 TRPA1 (0.63) TRPA1KDM4EPPARGPPARAALOX12
SCHEMBL16040410 1.00 TRPA1 (0.63) TRPA1KDM4EPPARGPPARAALOX12
SCHEMBL2540152 1.00 TRPA1 (0.63) TRPA1KDM4EPPARGPPARAALOX12
SCHEMBL370066 0.98 TRPA1 (0.66) TRPA1KDM4EPPARGPPARAALOX12
SCHEMBL370068 0.98 TRPA1 (0.66) TRPA1KDM4EPPARGPPARAALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4468884-A1 LYMPH-RELEASING COMPOSITIONS OF FATTY ACIDS AND USES THEREOF FOR LYMPHATIC INCORPORATION AND SYSTEMIC DISEASE TREATMENT Amarin Pharmaceuticals Ireland Limited (IE) 2024-12-04 EP claimed
CN-118714935-A Lymphoreleased fatty acid compositions and their use for lymphatic incorporation and systemic disease treatment 阿马里纳药物爱尔兰有限公司 2024-09-27 CN claimed
US-20240173285-A1 COMPOSITIONS COMPRISING EPA AND METHODS OF USING THE SAME FOR TREATING AND/OR PREVENTING ENDOTHELIAL DYSFUNCTION IN A SUBJECT AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) 2024-05-30 US claimed
EP-4329742-A1 COMPOSITIONS COMPRISING EPA AND METHODS OF USING THE SAME FOR TREATING AND/OR PREVENTING ENDOTHELIAL DYSFUNCTION IN A SUBJECT Amarin Pharmaceuticals Ireland Limited (IE) 2024-03-06 EP claimed
WO-2023146984-A1 LYMPH-RELEASING COMPOSITIONS OF FATTY ACIDS AND USES THEREOF FOR LYMPHATIC INCORPORATION AND SYSTEMIC DISEASE TREATMENT AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) 2023-08-03 WO claimed
WO-2022232633-A1 COMPOSITIONS COMPRISING EPA AND METHODS OF USING THE SAME FOR TREATING AND/OR PREVENTING ENDOTHELIAL DYSFUNCTION IN A SUBJECT AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) 2022-11-03 WO claimed
US-9308189-B2 Nitro fatty acids—neuroprotection and/or inhibition of cognitive decline NITROMEGA CORP. (US) 2016-04-12 US claimed
US-20140271844-A1 COMPOSITIONS CONTAINING NITRO FATTY ACIDS COMPLEXA, INC. 2014-09-18 US claimed
EP-2726086-A2 COMPOSITIONS CONTAINING NITRO FATTY ACIDS Nitromega Corp. (US) 2014-05-07 EP claimed
US-20140017219-A1 NITRO FATTY ACIDS - NEUROPROTECTION AND/OR INHIBITION OF COGNITIVE DECLINE NITROMEGA CORP. (US) 2014-01-16 US claimed
US-8563609-B2 Nitro fatty acids - neuroprotection and/or inhibition of cognitive decline NITROMEGA CORP. (US) 2013-10-22 US claimed
WO-2013003689-A2 COMPOSITIONS CONTAINING NITRO FATTY ACIDS NITROMEGA CORP. (US) 2013-01-03 WO claimed
US-20110280852-A1 NITRO FATTY ACIDS - NEUROPROTECTION AND/OR INHIBITION OF COGNITIVE DECLINE NITROMEGA CORP. (US) 2011-11-17 US claimed
EP-2384114-A1 NUTRACEUTICALS CONTAINING NITRO FATTY ACIDS Nitromega Corp. (US) 2011-11-09 EP claimed
US-20110256247-A1 TOPICAL COMPOSITIONS CONTAINING NITRO FATTY ACIDS NITROMEGA CORP. (US) 2011-10-20 US claimed
WO-2010078504-A1 NUTRACEUTICALS CONTAINING NITRO FATTY ACIDS NITROMEGA CORP. (US) 2010-07-08 WO claimed
US-20100166918-A1 NUTRACEUTICALS CONTAINING NITRO FATTY ACIDS COMPLEXA, INC. 2010-07-01 US claimed
JP-6212186-A None JP disclosed
US-20100166918-A1 NUTRACEUTICALS CONTAINING NITRO FATTY ACIDS COMPLEXA, INC. 2010-07-01 US disclosed
JP-H06212186-A PRODUCTION OF EICOSAPENTAENOIC ACID FROM RED ALGA FUDARAKU AGENCY OF IND SCIENCE & TECHNOL 1994-08-02 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140271844-A1 COMPOSITIONS CONTAINING NITRO FATTY ACIDS ALOX5, FASN, ALOX12 TRPA1 639/4885KDM4E 4550/4885PPARG 26/4885
US-20110256247-A1 TOPICAL COMPOSITIONS CONTAINING NITRO FATTY ACIDS ALOX5, FASN, FPR1 TRPA1 276/4885KDM4E 4447/4885PPARG 25/4885
US-20140017219-A1 NITRO FATTY ACIDS - NEUROPROTECTION AND/OR INHIBITION OF COGNITIVE DECLINE NLN, SMN1; SMN2, ELOVL1 TRPA1 1861/4885KDM4E 4231/4885PPARG 51/4885
US-20110280852-A1 NITRO FATTY ACIDS - NEUROPROTECTION AND/OR INHIBITION OF COGNITIVE DECLINE NLN, SMN1; SMN2, CASP10 TRPA1 1933/4885KDM4E 4215/4885PPARG 88/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.